Vallon Pharmaceuticals

Vallon Pharmaceuticals (Nasdaq: VLON) is a clinical-stage biopharmaceutical company focused on developing and commercializing tamper-resistant, abuse-deterrent formulations of ADHD medications. The company's lead product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine targeting the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. Vallon Pharmaceuticals is leveraging the clinical success of dextroamphetamine and is developing ADAIR through a streamlined 505(b)(2) U.S. FDA regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. If approved, ADAIR is anticipated to be the first abuse-deterrent, immediate-release formulation of dextroamphetamine. Founded in 2018, the industries the company operates in include Biopharma, Biotechnology, and Pharmaceutical. For further details, inquiries can be directed to [email protected].